Targeting HER 2 and angiogenesis in gastric cancer
1a Department of Surgery, Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC) , Medical University of Vienna , Vienna , Austria.
Abstract:
Gastric cancer is one of the most commonly diagnosed and the second leading cause of cancer death worldwide. Surgery combined with multimodal therapy remains the only curative therapy. However, local relapse or distant metastases occur in more than 50% of radically resected patients. Due to molecular therapies, targeting HER2 and angiogenesis, major advances in the treatment of gastric cancer could be achieved. Nevertheless, development of resistance to monoclonal antibodies, such as trastuzumab, is arising. Currently a number of promising new therapeutic are under investigation, combining chemotherapy with newly developed agents to overcome cancer resistance. In this review we report current clinical applications of targeted therapies and overview ongoing trials, investigating the use of monoclonal antibodies in (HER2 positive) gastric cancer.
Insights
Gastric cancer treatment advances include targeted therapies like trastuzumab. This review covers current applications and ongoing trials for monoclonal antibodies in HER2-positive gastric cancer, addressing resistance challenges.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Gastric cancer is a leading cause of cancer death globally.
- While surgery offers curative potential, over 50% of patients experience relapse or metastasis.
- Advances in molecular therapies targeting HER2 and angiogenesis have improved treatment outcomes.
Purpose of the Study:
- To review current clinical applications of targeted therapies in gastric cancer.
- To overview ongoing clinical trials investigating monoclonal antibodies for gastric cancer treatment.
- To address the emerging challenge of resistance to targeted therapies like trastuzumab.
Main Methods:
- Literature review of current clinical applications of targeted therapies.
- Analysis of ongoing clinical trials for monoclonal antibodies in gastric cancer.
- Examination of resistance mechanisms to targeted agents.
Main Results:
- Targeted therapies, particularly those against HER2, have shown significant progress in gastric cancer treatment.
- Resistance to monoclonal antibodies like trastuzumab is a growing concern.
- New therapeutic strategies combining chemotherapy with novel agents are under investigation to overcome resistance.
Conclusions:
- Monoclonal antibodies represent a key strategy in treating HER2-positive gastric cancer.
- Overcoming resistance to targeted therapies is crucial for improving patient outcomes.
- Ongoing research focuses on novel combination therapies to enhance efficacy and manage resistance in gastric cancer.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:38Mitogens and the Cell Cycle